The University of Chicago Header Logo

Connection

Ravi Salgia to Gene Expression Regulation, Neoplastic

Back to Details
This is a "connection" page, showing publications Ravi Salgia has written about Gene Expression Regulation, Neoplastic.
Ravi Salgia
Connection Strength
3.690
Gene Expression Regulation, Neoplastic
  1. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734.
    View in: PubMed
    Score: 0.408
  2. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. Sci Rep. 2015 Jun 15; 5:10641.
    View in: PubMed
    Score: 0.361
  3. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210.
    View in: PubMed
    Score: 0.298
  4. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem. 2010 Jun 11; 285(24):18575-85.
    View in: PubMed
    Score: 0.251
  5. Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Mol Cancer Ther. 2021 10; 20(10):1820-1835.
    View in: PubMed
    Score: 0.137
  6. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021 01 19; 2(1):100186.
    View in: PubMed
    Score: 0.133
  7. Activating p53 function by targeting RLIP. Biochim Biophys Acta Rev Cancer. 2021 04; 1875(2):188512.
    View in: PubMed
    Score: 0.133
  8. Therapeutic targeting of miRNA-216b in cancer. Cancer Lett. 2020 08 01; 484:16-28.
    View in: PubMed
    Score: 0.127
  9. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
    View in: PubMed
    Score: 0.123
  10. 2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells. J Proteomics. 2019 02 10; 192:233-245.
    View in: PubMed
    Score: 0.113
  11. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
    View in: PubMed
    Score: 0.109
  12. EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer. 2018 Apr; 1869(2):128-137.
    View in: PubMed
    Score: 0.108
  13. PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. J Biol Chem. 2015 Sep 04; 290(36):21901-14.
    View in: PubMed
    Score: 0.091
  14. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer. 2014 Mar 14; 14:185.
    View in: PubMed
    Score: 0.083
  15. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84.
    View in: PubMed
    Score: 0.081
  16. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014 Feb 01; 74(3):884-95.
    View in: PubMed
    Score: 0.081
  17. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett. 2014 Feb 01; 343(1):14-23.
    View in: PubMed
    Score: 0.080
  18. MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1089-96.
    View in: PubMed
    Score: 0.077
  19. PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res. 2010 Apr; 23(2):225-37.
    View in: PubMed
    Score: 0.062
  20. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res. 2009 Oct 01; 69(19):7538-47.
    View in: PubMed
    Score: 0.060
  21. PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. J Biol Chem. 2009 Oct 02; 284(40):27524-32.
    View in: PubMed
    Score: 0.060
  22. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 2009 Mar; 89(3):301-14.
    View in: PubMed
    Score: 0.058
  23. FYN is overexpressed in human prostate cancer. BJU Int. 2009 Jan; 103(2):171-7.
    View in: PubMed
    Score: 0.057
  24. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2007 Jun; 292(6):L1488-94.
    View in: PubMed
    Score: 0.051
  25. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res. 2006 Dec 15; 12(24):7261-70.
    View in: PubMed
    Score: 0.050
  26. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology. 2006 Nov; 11(6):687-92.
    View in: PubMed
    Score: 0.050
  27. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005 Feb 15; 65(4):1479-88.
    View in: PubMed
    Score: 0.044
  28. MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis. Mol Cancer. 2023 01 04; 22(1):1.
    View in: PubMed
    Score: 0.038
  29. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 08; 125(4):582-592.
    View in: PubMed
    Score: 0.034
  30. MicroRNA-1: Diverse role of a small player in multiple cancers. Semin Cell Dev Biol. 2022 04; 124:114-126.
    View in: PubMed
    Score: 0.034
  31. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020 07 13; 38(1):79-96.e11.
    View in: PubMed
    Score: 0.032
  32. AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. Clin Cancer Res. 2020 08 15; 26(16):4349-4359.
    View in: PubMed
    Score: 0.032
  33. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 1999 Dec 15; 94(12):4233-46.
    View in: PubMed
    Score: 0.031
  34. 2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. Mol Carcinog. 2018 12; 57(12):1751-1762.
    View in: PubMed
    Score: 0.028
  35. Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. Int J Cancer. 2017 08 15; 141(4):766-777.
    View in: PubMed
    Score: 0.026
  36. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
    View in: PubMed
    Score: 0.024
  37. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget. 2016 Mar 22; 7(12):13621-33.
    View in: PubMed
    Score: 0.024
  38. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12.
    View in: PubMed
    Score: 0.022
  39. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. Int J Gynecol Pathol. 2012 Jan; 31(1):15-24.
    View in: PubMed
    Score: 0.018
  40. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011 Aug 15; 17(16):5257-67.
    View in: PubMed
    Score: 0.017
  41. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res. 2011 May 15; 17(10):3112-22.
    View in: PubMed
    Score: 0.017
  42. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer. 2008 Sep-Oct; 18(5):976-84.
    View in: PubMed
    Score: 0.013
  43. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene. 2002 Feb 21; 21(9):1423-33.
    View in: PubMed
    Score: 0.009
  44. BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood. 2000 Dec 15; 96(13):4328-34.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.